Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA.
James R Berenson, MD Inc, West Hollywood, CA, USA.
Eur J Haematol. 2018 Jun;100(6):621-623. doi: 10.1111/ejh.13058. Epub 2018 Apr 25.
To evaluate the efficacy and safety of elotuzumab and dexamethasone (Ed) for relapsed or refractory multiple myeloma (RRMM) patients.
This retrospective study evaluated the efficacy and safety of Ed treatment for 21 RRMM patients, 11 of whom were considered lenalidomide-refractory, and all of whom had progressed on at least 1 prior steroid-containing regimen. We also evaluated the efficacy of adding lenalidomide to a subset of patients following progression from Ed.
The overall response rate (ORR) and clinical benefit rate (CBR) of Ed were 10% and 19%, respectively. An additional 52% of patients demonstrated stable disease as their best response. The median PFS was 1.8 months on Ed for all patients. Fifteen patients received ERd following progression on Ed, and 60% of these patients were lenalidomide-refractory. The ORR and CBR were 20% and 33%, respectively, and the median PFS was 3.4 months.
Our results suggest that some patients can benefit from Ed without an accompanying immunomodulatory agent and that efficacy can be achieved with the addition of lenalidomide at the time of progression. No new safety signals were detected, except for thrombocytopenia in 1 patient on Ed.
评估依鲁替尼联合地塞米松（Ed）治疗复发/难治性多发性骨髓瘤（RRMM）患者的疗效和安全性。
本回顾性研究评估了 21 例 RRMM 患者接受 Ed 治疗的疗效和安全性，其中 11 例为来那度胺难治性，所有患者均在至少 1 种含皮质类固醇的方案治疗后进展。我们还评估了在 Ed 治疗进展后，将来那度胺加入部分患者的疗效。
Ed 的总缓解率（ORR）和临床获益率（CBR）分别为 10%和 19%。另外 52%的患者最佳缓解为疾病稳定。所有患者 Ed 的中位无进展生存期（PFS）为 1.8 个月。15 例患者在 Ed 治疗进展后接受 ERd，其中 60%的患者为来那度胺难治性。ORR 和 CBR 分别为 20%和 33%，中位 PFS 为 3.4 个月。
我们的结果表明，一些患者可以在没有免疫调节剂的情况下从 Ed 中获益，并且在进展时添加来那度胺可以获得疗效。除了 1 例 Ed 患者发生血小板减少外，未发现新的安全性信号。
